• • 

  • Oxaplin(oxaliplatin)

    ETC Drugs > Anti-malignant-tumor agent

    oxaliplatin

    • Product inquiry
• • Key Information

  • Ingredients oxaliplatin 50mg Indication 1. 5-fluorouracil and folinic acid (leucovorin) jointly administered as a stage I treatment for metastatic colon, rectal cancer 2. 5-fluorouracil and folinic acid(leucovorin) jointly administrated as an adjuvant treatment for stage III (Duke’s C) colinitis after complete resection of the primary tumor surgery dosage and administration 1. 5-fluorouracil and folinic acid (leucovorin) jointly administered as a stage I treatment for metastatic colon, rectal cancer: 85mg/㎡ recommended to be intravenously injected every 2 weeks 2. 5-fluorouracil and folinic acid(leucovorin) jointly administrated as an adjuvant treatment for stage III (Duke’s C) colinitis after complete resection of the primary tumor surgery: Usage every 2 weeks recommended as follows for a 12-week period (6 months): Day 1: Drip-infuse approximately 85mg/m2 of the medication and simultaneously drip-infuse leucovorin 200mg/m2 to a separate bag for 2 hours, and then intravenously inject 5-fluorouracil 400mg/m2 to the bolus, and drip-infuse 5-fluorouracil 600mg/m2 for 22 hours. Day 2: Administer leucovorin and 5-fluorouracil as directed for Day 1 (leucovorin 200mg/m2 drip-infused for 2 hours, followed by 5-fluorouracil 400mg/m2 intravenously injected to the bolus, and 5-fluorouracil 600mg/m2 drip-infused for 22 hours).? The dosage should be controlled according to dose tolerance. This medication must always be administered before 5-fluorouracil. The medication must be recomposed and diluted using the recommended solvent before being administered. Dilute the medication to 250-500ml of a 5% glucose solution, and then intravenously administer for 2-6 hours through either the periphery or central vein. This medication is mainly jointly administered using a continuous drip-infusion method for 5-fluorouracil.? A infused method should be used during medication-use every 2 weeks, followed by administration of 5-fluorouracil to the bolus. In the case an extravasation occurs, use of the medication should be stopped. Renal injury patient: This medication was not researched with a target on severe renal injury patients.? Normal recommended levels of the medication can be administered for patients of secondary level renal injuries, but an appropriate control of dosages is recommended for weak renal injury patients. Liver malfunction patient: This medication was not researched with a target on severe liver malfunction patients. However, according to examination results of abnormal liver-function patients administered with this drug, patients did not show signs of increased acute virulence.? There was no separate dosage control for liver malfunction patients during the development of this medication. Elderly: In the case this medication was administered alone or jointly with 5-fluorouracil, secondary levels of virulence did not appear for patients of ages 65 and older.? Thus, a separate dosage control is not particularly needed for senior patients.

List